QT Variability Pre and Post Cardioversion

Atrial Fibrillation Clinical Trial

— DCCV  

Official title:

QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00885391
• Other study ID #: 060908
• Secondary ID: RO1-HL085690-01A
• Status: Completed
• Phase: N/A
• First received: April 20, 2009
• Last updated: December 9, 2014
• Start date: January 2007
• Est. completion date: March 2012

Study information

• Verified date: December 2014
• Source: Vanderbilt University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Description:

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 219
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• At least 21 years of age

• Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

• Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability

• Undergoing DC-Cardioversion for post-cardiac surgery

• Dual chamber pacemakers

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (3)

Lead Sponsor	Collaborator
Vanderbilt University	National Institutes of Health (NIH), Wake Forest School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	QT variability before and after direct current cardioversion		1.5	No